The product, marketed as Sirdupla in the United Kingdom, is the generic version of GSK’s beta agonist and corticosteroid combination treatment for asthma.
Mylan N.V. announced that it has launched a bioequivalent alternative to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate). According to Mylan, this is the first generic version of the most commonly prescribed long-acting beta agonist and inhaled corticosteroid pressurized metered-dose inhaler (pMDI) asthma therapy in the United Kingdom. The product will be marketed under the brand name Sirdupla in the UK and is indicated for the treatment and prevention of asthma symptoms in adults 18 years and older.
3M Drug Delivery Systems will be manufacturing the product. Filling, assembly, and packaging of Sirdupla will be done at 3M’s manufacturing facility in Loughborough, UK.
